Paclitaxel

Catalog No.S1150 Synonyms: NSC 125973

Molecular Weight(MW): 853.91

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Cited by 25 Publications

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Sci Transl Med, 2018, 10(433)

PubMed: 29563317 ( click the link to review the publication )

Science, 2017, eaal3755

PubMed: 28302793 ( click the link to review the publication )

Nat Chem Biol, 2016, 10.1038/nchembio.2082

PubMed: 27182663 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(13):3197-3203

PubMed: 29559562 ( click the link to review the publication )

Clin Cancer Res., 2017, 23(15):4364-4375

PubMed: 28246274 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2015, 10.1021/am5090226

PubMed: 25811662 ( click the link to review the publication )

J Control Release, 2019, 294:165-175

PubMed: 30557650 ( click the link to review the publication )

Biomacromolecules, 2014, 15(11):4187-94

PubMed: 25251833 ( click the link to review the publication )

Int J Radiat Oncol, 2015, 91(4):807-16

PubMed: 25752395 ( click the link to review the publication )

Biochem Pharmacol, 2015, 10.1016/j.bcp.2015.05.005

PubMed: ( click the link to review the publication )

Am J Cancer Res, 2017, 7(4):903-912

PubMed: 28469962 ( click the link to review the publication )
Mol Pharmacol, 2014, 85(3):408-19

PubMed: 24353313 ( click the link to review the publication )

Mol Pharmacol, 2014, 85(3):408-19

PubMed: 24353313 ( click the link to review the publication )

Surgery, 2014, 10.1016/j.surg.2014.10.007

PubMed: ( click the link to review the publication )

Am J Physiol Heart Circ Physiol, 2012, 71(13):4707-19

PubMed: 21555371 ( click the link to review the publication )

Life Sci, 2019, 224:255-262

PubMed: 30928404 ( click the link to review the publication )

BMC Cancer, 2012, 12:541

PubMed: 23171055 ( click the link to review the publication )

RSC Adv, 2011, 1:884-892

PubMed: ( click the link to review the publication )

Bioorg Med Chem, 2012, 21(4):922-31

PubMed: 23306053 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155052

PubMed: 27148873 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123901

PubMed: 25875914 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 453(3):392-7

PubMed: 25268318 ( click the link to review the publication )

J Nanopart Res, 2014, 16:2340

PubMed: ( click the link to review the publication )
Orthop Surg, 2019, 11(1):126-134

PubMed: 30592172 ( click the link to review the publication )

6 Customer Reviews

(F) Kaplan-Meier curves are shown for all groups described: no hydrogel, a hydrogel loaded with paclitaxel, or a hydrogel loaded with doxorubicin. The number of mice per group (n) and median survival (ms) are listed. The experiment was performed at least three times.

Science, 2018, 10(433), doi: 10.1126/scitranslmed.aar1916. Paclitaxel purchased from Selleck.

Effect of tivantinib on the mitotic index was compared with the antimitotic drugs paclitaxel and vinblastine after overnight treatment of the HLE cell line with two different concentrations of each drug.

Clin Cancer Res, 2017, 23(15):4364-4375. Paclitaxel purchased from Selleck.
Characterization of nuclear damage by PARP as DNA damage repair marker. CLSM images of dual drug conjugated nanoparticle treatments to HeLa cells for 24 h at their respective IC50 drug dosages compared to nontreated control. Cells were stained with PARP-Alexafluor 488 antibody (green).

ACS Appl Mater Interfaces, 2015, 7(14): 7584-98. Paclitaxel purchased from Selleck.

Inhibitory effect of lenvatinib and paclitaxel on the proliferation of ATC cells. Cells were treated with the indicated concentrations of lenvatinib (A) and paclitaxel (B) for 48 h, followed by MTT assay to evaluate cell proliferation. IC50 values of these two drugs for each cell line were calculated using the Reed-Muench method

Am J Cancer Res, 2017, 7(4):903-912. Paclitaxel purchased from Selleck.
Western blot analysis of pPRAS40 (T246), pS6 (S240/S244), and pS6 (S235/S236) proteins in (A) HeyA8 cells and (B) SKOV3 cells treated with 0.37 μM or 10 μM paclitaxel in three-dimensional cell culture for 24 hours.

PLoS One, 2016, 11(5):e0155052. . Paclitaxel purchased from Selleck.

Microscope image (406) magnification of U937 cells after exposure to SM-TNs. a) Untreated U937 cells. b) U937 cells treated with 200 nM, and 35 nM ODS empty shells. c) U937 cells treated with microcrystalline (free) Taxol prepared by sonicating Taxol in 20%H3PO4/0.8% SDS solution. d) U937 cells treated with 200 nM SM-TN. A SM-TN is seen in the middle of the picture. e) U937 cells treated with 35 nM SMTN.The nanowires are too small to see at this magnification, but their effect on the cells is clearly visible. Scale bar = 10 mm.

RSC Adv 2011 1, 884-892. Paclitaxel purchased from Selleck.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Targets

Microtubule (human endothelial cells) ^[1]

0.1 pM

In vitro

Paclitaxel inhibits non-endothelial type human cells at 10⁴ - to 10⁵ -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. ^[1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. ^[2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
TE-15	M1LsZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;pXGZZUUN3ME2wMlAxODJ6NzFOwG0>	NELtTGVUSU6JRWK=
LC-2-ad	M2m0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTBwMECwN\|E4KM7:TR?=	M4PmbnNCVkeHUh?=
RL95-2	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWr6Rmw1UUN3ME2wMlAxODZ4ODFOwG0>	NVLVOphpW0GQR1XS
MZ1-PC	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlzwTWM2OD1yLkCwNFczQSEQvF2=	MWTTRW5ITVJ?
TE-8	NVfGbmE{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHJRVdMUUN3ME2wMlAxOTF5IN88US=>	M{nmSXNCVkeHUh?=
SW954	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFTTO49KSzVyPUCuNFAyOTlizszN	MXPTRW5ITVJ?
TE-11	MorzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4i3emlEPTB;MD6wNFEzOyEQvF2=	MoHRV2FPT0WU
PSN1	NVzOTI53T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUDJR\|UxRTBwMECxN{DPxE1?	M1\wN3NCVkeHUh?=
MOLT-4	M3f4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3LlOmlEPTB;MD6wNFE1QSEQvF2=	M{G2S3NCVkeHUh?=
697	M4jGeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlu0TWM2OD1yLkCwNVUh\|ryP	NEnQNYZUSU6JRWK=
ETK-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUXSZ5BHUUN3ME2wMlAxOTV{IN88US=>	MWDTRW5ITVJ?
TE-10	NX7RWWpFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoGzTWM2OD1yLkCwNVU1KM7:TR?=	NX;4TGtmW0GQR1XS
HUTU-80	M2W3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTBwMECxOlgh\|ryP	MV\TRW5ITVJ?
NTERA-S-cl-D1	NH;WZ2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3XvZWlEPTB;MD6wNFIxQSEQvF2=	MYjTRW5ITVJ?
MFH-ino	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTBwMECyOlgh\|ryP	MWDTRW5ITVJ?
IA-LM	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHGTWM2OD1yLkCwNlgh\|ryP	MULTRW5ITVJ?
MC116	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkezTWM2OD1yLkCwNlg6KM7:TR?=	NYO2d3U{W0GQR1XS
RKO	MmqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfR[\|BKSzVyPUCuNFAzQThizszN	MUnTRW5ITVJ?
MRK-nu-1	M1\nVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXjJR\|UxRTBwMECyPVkh\|ryP	MlnTV2FPT0WU
VA-ES-BJ	NIHvb4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnrqTWM2OD1yLkCwN{DPxE1?	M1f3S3NCVkeHUh?=
KALS-1	NEX0[IhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTBwMECzNFgh\|ryP	MoTyV2FPT0WU
BB30-HNC	MljVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NITWXZVKSzVyPUCuNFA{OTRizszN	NH7BVGNUSU6JRWK=
ACN	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml3tTWM2OD1yLkCwN\|E3KM7:TR?=	MX;TRW5ITVJ?
TE-9	NVjWNG51T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHrkXFRKSzVyPUCuNFA{OjZizszN	MWHTRW5ITVJ?
SIG-M5	NEn5b5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPFTWM2OD1yLkCwN\|I4KM7:TR?=	MY\TRW5ITVJ?
no-10	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTBwMECzOlIh\|ryP	NIPhdoNUSU6JRWK=
EW-1	NFHlSpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LlXWlEPTB;MD6wNFM4OSEQvF2=	NXHYO4M{W0GQR1XS
SK-LMS-1	M1vMZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIn4OoVKSzVyPUCuNFA1ODFizszN	NWe5OZd5W0GQR1XS
GT3TKB	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTBwMEC0N\|Qh\|ryP	Mkf0V2FPT0WU
ES4	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7hdZpiUUN3ME2wMlAxPDR7IN88US=>	NYTrXXAyW0GQR1XS
IMR-5	NXP6VY9nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYfJd5lYUUN3ME2wMlAxPDVizszN	NVjPOWtOW0GQR1XS
NCI-H1648	NEXZd4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWLTRpZYUUN3ME2wMlAxPDZ7IN88US=>	MnrVV2FPT0WU
MV-4-11	NXXvVmZQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTBwMEC0O\|Uh\|ryP	M4XvOXNCVkeHUh?=
SK-UT-1	M1zXOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYDrcldyUUN3ME2wMlAxPDhizszN	MXrTRW5ITVJ?
NB13	NYixZZRGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEOwNHBKSzVyPUCuNFA1QTFizszN	M2TUXXNCVkeHUh?=
DJM-1	Mlr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnrUTWM2OD1yLkCwOVMh\|ryP	M3mxenNCVkeHUh?=
ES8	M3PoS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlX3TWM2OD1yLkCwOVM5KM7:TR?=	M4LEfnNCVkeHUh?=
TE-6	M1fHVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV3TU3lCUUN3ME2wMlAxPTdizszN	MVrTRW5ITVJ?
KS-1	MlPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2D1R2lEPTB;MD6wNFU5OiEQvF2=	NVjmWZJpW0GQR1XS
TE-1	MlXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUC3Z3NMUUN3ME2wMlAxPjB4IN88US=>	M1e2fXNCVkeHUh?=
ATN-1	NHfQRVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\hUWlEPTB;MD6wNFYxQSEQvF2=	M1PoNXNCVkeHUh?=
A4-Fuk	NEnmT2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTBwMEC2NVEh\|ryP	MnXHV2FPT0WU
ALL-PO	NYfseo9zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4G2eWlEPTB;MD6wNFY{KM7:TR?=	NXfse2d6W0GQR1XS
BE-13	NIrQOJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn\PTWM2OD1yLkCwOlM3KM7:TR?=	NIK2VmlUSU6JRWK=
KM12	NELvb45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjXSnJPUUN3ME2wMlAxPjN5IN88US=>	M2rBRXNCVkeHUh?=
NOS-1	NEXB[IVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mne1TWM2OD1yLkCwOlUh\|ryP	MUPTRW5ITVJ?
SW962	NUiySoJYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjrTWM2OD1yLkCwOlYzKM7:TR?=	MULTRW5ITVJ?
OCUB-M	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVfJR\|UxRTBwMEC2OlIh\|ryP	MkDrV2FPT0WU
NCI-H510A	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTBwMEC2OlUh\|ryP	Mn\xV2FPT0WU
EW-16	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vhU2lEPTB;MD6wNFY6PCEQvF2=	Mnq4V2FPT0WU
KGN	NFnRW2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTBwMEC3NVIh\|ryP	M1fxdHNCVkeHUh?=
LS-411N	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHLy[IpKSzVyPUCuNFA4OTdizszN	M2\vTXNCVkeHUh?=
Becker	M1ftUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1GxOGlEPTB;MD6wNFczKM7:TR?=	NUXBfIFoW0GQR1XS
HC-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnZWnJoUUN3ME2wMlAxPzJzIN88US=>	MlXJV2FPT0WU
CESS	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfPTHNjUUN3ME2wMlAxPzN5IN88US=>	NIrMNVRUSU6JRWK=
KURAMOCHI	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYfFeGVqUUN3ME2wMlAxPzR6IN88US=>	NYPqU\|FvW0GQR1XS
TGBC24TKB	MofpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTBwMEC3OVIh\|ryP	NGjOZWNUSU6JRWK=
SW982	NVe1TFRFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmjLTWM2OD1yLkCwO\|Y3KM7:TR?=	M4DSWXNCVkeHUh?=
HCE-4	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{nUZ2lEPTB;MD6wNFc3PyEQvF2=	MXHTRW5ITVJ?
LOUCY	MnK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo\qTWM2OD1yLkCwO\|c2KM7:TR?=	NV7teIdsW0GQR1XS
8-MG-BA	M13ifmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmjFTWM2OD1yLkCwO\|k3KM7:TR?=	M{nFfHNCVkeHUh?=
HT-144	MnGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWmy[49tUUN3ME2wMlAxQCEQvF2=	NYrvc3pDW0GQR1XS
LXF-289	NF3ocY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkDSTWM2OD1yLkCwPFE5KM7:TR?=	MnjhV2FPT0WU
RS4-11	MlP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoH1TWM2OD1yLkCwPFM3KM7:TR?=	Mmr6V2FPT0WU
DEL	M4LtXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn[zTWM2OD1yLkCwPFQ2KM7:TR?=	NFn1bmtUSU6JRWK=
OCI-AML2	NIThOmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXLPfZlyUUN3ME2wMlAxQDV{IN88US=>	NUHQe3ExW0GQR1XS
CCRF-CEM	NHvYRVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVL3eZpZUUN3ME2wMlAxQDdzIN88US=>	NUOwN\|dlW0GQR1XS
A388	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXexV3g1UUN3ME2wMlAxQDd2IN88US=>	MlXpV2FPT0WU
KNS-42	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYDmPXRkUUN3ME2wMlAxQDlzIN88US=>	NX;FWIVRW0GQR1XS
OVCAR-4	NUH3SWJjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVXabXdwUUN3ME2wMlAxQTB2IN88US=>	MoXtV2FPT0WU
NCI-H1355	MkDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{jvbGlEPTB;MD6wNFkyPCEQvF2=	M4G5T3NCVkeHUh?=
BL-70	NXHyW5puT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUPJR\|UxRTBwMEC5N{DPxE1?	M2Dq[nNCVkeHUh?=
BL-41	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLqcG5KSzVyPUCuNFA6OzRizszN	MUXTRW5ITVJ?
A101D	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTBwMEC5OkDPxE1?	NW\Te\|M6W0GQR1XS
HL-60	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPoXXh6UUN3ME2wMlAxQTZ4IN88US=>	NEi1[\|lUSU6JRWK=
COR-L279	NHnrcnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYHJR\|UxRTBwMEC5PVkh\|ryP	NWD2U\|UyW0GQR1XS
NCI-SNU-16	NFuw[FVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{jWcmlEPTB;MD6wNVAxQCEQvF2=	M{nxdHNCVkeHUh?=
Calu-6	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfoRW17UUN3ME2wMlAyODF{IN88US=>	MWTTRW5ITVJ?
SR	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXu0U5lUUUN3ME2wMlAyODJ4IN88US=>	NF\TTolUSU6JRWK=
QIMR-WIL	MkKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDiTWM2OD1yLkCxNFM{KM7:TR?=	Mn73V2FPT0WU
LB647-SCLC	NVS0NJFyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7MOI1DUUN3ME2wMlAyODVzIN88US=>	NVrQd3RoW0GQR1XS
RPMI-8226	M{PITWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGXV[YZKSzVyPUCuNFEyODJizszN	MmG1V2FPT0WU
SK-PN-DW	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTBwMEGxNVIh\|ryP	MVnTRW5ITVJ?
SF268	M{TZV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTBwMEGxOVEh\|ryP	NXXT[Jl{W0GQR1XS
HD-MY-Z	MkHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUH1PXRzUUN3ME2wMlAyOTZ\|IN88US=>	NWfPRlhXW0GQR1XS
DOHH-2	NXf4RVRUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLl[4FvUUN3ME2wMlAyOjB\|IN88US=>	NFLteJdUSU6JRWK=
SCC-3	NEe2VHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVLlTFRbUUN3ME2wMlAyOjB2IN88US=>	MlX2V2FPT0WU
ST486	Mm\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHPHc4JKSzVyPUCuNFEzODRizszN	MmPLV2FPT0WU
NALM-6	NIiwW5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnTbpJKSzVyPUCuNFEzOTRizszN	NXvuO3g5W0GQR1XS
NCI-H1436	NVvXfll6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVrOSGZOUUN3ME2wMlAyOjNzIN88US=>	M2HHPXNCVkeHUh?=
KE-37	M37Sd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XWRmlEPTB;MD6wNVI{PCEQvF2=	NU\Qc4RIW0GQR1XS
RPMI-8402	NGrMXVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33y[2lEPTB;MD6wNVI2PiEQvF2=	NWnrbGdHW0GQR1XS
RXF393	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkHZTWM2OD1yLkCxNlU4KM7:TR?=	NIXTeXNUSU6JRWK=
KARPAS-45	M3rkPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTBwMEGyO{DPxE1?	NF2zc5BUSU6JRWK=
HOP-62	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEO4[pFKSzVyPUCuNFEzPzZizszN	NIHvOoRUSU6JRWK=
ES1	NWX4Sox{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4HPUGlEPTB;MD6wNVI5QCEQvF2=	M3jJXHNCVkeHUh?=
L-363	MoL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LkV2lEPTB;MD6wNVM2OSEQvF2=	MmXvV2FPT0WU
GI-1	NXLyRYpNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;KcVVKSzVyPUCuNFE{PzNizszN	MWTTRW5ITVJ?
CTV-1	MnTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIrHRmdKSzVyPUCuNFE1PzhizszN	MmXTV2FPT0WU
TE-5	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jyd2lEPTB;MD6wNVQ6PiEQvF2=	Mle0V2FPT0WU
SNU-C2B	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYq3cHQ4UUN3ME2wMlAyPDl4IN88US=>	M4TWTHNCVkeHUh?=
K-562	NIrlcIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEX6eJRKSzVyPUCuNFE2OTZizszN	NXLnbYU{W0GQR1XS
SNB75	M4PLWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzFT2duUUN3ME2wMlAyPTRizszN	M1;LS3NCVkeHUh?=
MOLT-13	M3HEUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{i1OWlEPTB;MD6wNVY{PyEQvF2=	MnXHV2FPT0WU
LS-123	NVfSTFhGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV[wNmRDUUN3ME2wMlAyPjZ2IN88US=>	MYLTRW5ITVJ?
NCI-SNU-5	NYDuOVZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{m1dGlEPTB;MD6wNVcxOSEQvF2=	M4fqdHNCVkeHUh?=
Daudi	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\nPGlEPTB;MD6wNVcxQCEQvF2=	MV3TRW5ITVJ?
A253	MlPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1TSfmlEPTB;MD6wNVc{QCEQvF2=	MXTTRW5ITVJ?
TGBC1TKB	NITIdnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWGwU2RHUUN3ME2wMlAyPzV{IN88US=>	NXSxV2RsW0GQR1XS
SJSA-1	NIXjNJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\CZnlKSzVyPUCuNFE4PjdizszN	NFvHfmNUSU6JRWK=
NCCIT	NUHG[JdmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1e0bGlEPTB;MD6wNVc3QSEQvF2=	MV3TRW5ITVJ?
NCI-H69	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mon4TWM2OD1yLkCxO\|c5KM7:TR?=	NFjwdYdUSU6JRWK=
SH-4	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHq2TZFKSzVyPUCuNFE5QTVizszN	NIfteFRUSU6JRWK=
HCC1187	MnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTBwMEG5NlQh\|ryP	MmfLV2FPT0WU
HCC1599	NI\DNWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTBwMEKwNkDPxE1?	M{\OTHNCVkeHUh?=
ONS-76	MkH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTBwMEKwN\|Yh\|ryP	MkLrV2FPT0WU
KU812	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWi1RmZ{UUN3ME2wMlAzODN7IN88US=>	NXHGZ2ZtW0GQR1XS
ML-2	Mn7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\WUYl[UUN3ME2wMlAzODR5IN88US=>	NG\Qd2dUSU6JRWK=
HCE-T	M3;NbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTBwMEKwPVIh\|ryP	NWTCTVZrW0GQR1XS
NCI-H446	NGDxZ\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF74WpRKSzVyPUCuNFIyOTJizszN	NGjmR29USU6JRWK=
RPMI-6666	NXHQN4xrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX[0RohqUUN3ME2wMlAzOTR7IN88US=>	MVzTRW5ITVJ?
MOLT-16	NH\ZbpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzPV2lKSzVyPUCuNFIyPTNizszN	NIK3Zm1USU6JRWK=
JiyoyeP-2003	M2XXOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWr6XVhnUUN3ME2wMlAzOTd4IN88US=>	NYixSVByW0GQR1XS
MHH-PREB-1	NFniPHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRTBwMEKxPVEh\|ryP	NWf0bopGW0GQR1XS
MC-CAR	NFjufZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NELP[IdKSzVyPUCuNFI{OjZizszN	NX7SWnl3W0GQR1XS
BC-3	NUX2UZVoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUH3SoJpUUN3ME2wMlAzOzR2IN88US=>	M4\QPXNCVkeHUh?=
KINGS-1	M17lPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1y3R2lEPTB;MD6wNlM2PSEQvF2=	MXnTRW5ITVJ?
PF-382	NFSyPFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTBwMEKzO\|gh\|ryP	MXXTRW5ITVJ?
J-RT3-T3-5	M3\pTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVu2XZNZUUN3ME2wMlAzOzh\|IN88US=>	NGq0NodUSU6JRWK=
SF539	NXHMWpNJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4f6PGlEPTB;MD6wNlQxOSEQvF2=	M4DHOXNCVkeHUh?=
LB831-BLC	M3zYeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn65TWM2OD1yLkCyOFg2KM7:TR?=	NGD0UFNUSU6JRWK=
DMS-114	NFTadXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;i[GpjUUN3ME2wMlAzPTB{IN88US=>	MlnDV2FPT0WU
LB1047-RCC	NUDqR5NtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvib\|BKSzVyPUCuNFI2OSEQvF2=	NUnpO2Z3W0GQR1XS
LB771-HNC	MlvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkC4TWM2OD1yLkCyOVM1KM7:TR?=	NGDU[JZUSU6JRWK=
BB65-RCC	NVPaR4VZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIrQUZlKSzVyPUCuNFI2OzRizszN	MUjTRW5ITVJ?
BV-173	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{OyeWlEPTB;MD6wNlU2PCEQvF2=	NW[wSZY6W0GQR1XS
ARH-77	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUPQfpBOUUN3ME2wMlAzPjBzIN88US=>	NHjwblNUSU6JRWK=
IST-MEL1	NEj6SIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTBwMEK2NlMh\|ryP	MYTTRW5ITVJ?
NB1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkfMTWM2OD1yLkCyOlg4KM7:TR?=	NGXwNItUSU6JRWK=
EoL-1-cell	MkW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTBwMEK2PFgh\|ryP	MoOxV2FPT0WU
KY821	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHXZfWFKSzVyPUCuNFI3QTdizszN	M2TiV3NCVkeHUh?=
CMK	M17sPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\Fc25JUUN3ME2wMlAzPzN2IN88US=>	NXHkd4tDW0GQR1XS
NCI-H2126	NYm1[VlVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTBwMEK3Olgh\|ryP	MoPNV2FPT0WU
NCI-H526	NVPEeXlkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlnrTWM2OD1yLkCyPFkyKM7:TR?=	MnTiV2FPT0WU
COLO-684	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFjqW\|FKSzVyPUCuNFI6ODhizszN	MYfTRW5ITVJ?
NCI-H747	M2C1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTBwMEK5N\|Mh\|ryP	MVjTRW5ITVJ?
JAR	Mn\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3X0OmlEPTB;MD6wNlk1PiEQvF2=	M1nNWXNCVkeHUh?=
MEG-01	Mly5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDQOWhOUUN3ME2wMlAzQTd6IN88US=>	NXjFNW1vW0GQR1XS
MONO-MAC-6	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mlf3TWM2OD1yLkCzNFI{KM7:TR?=	M1fnPXNCVkeHUh?=
IST-SL1	NIPVTJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjBOWM1UUN3ME2wMlA{ODR{IN88US=>	MmixV2FPT0WU
CPC-N	M3v0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGHlXIRKSzVyPUCuNFMxPzlizszN	M{DaTnNCVkeHUh?=
NCI-H1963	M4rIdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGG1OG1KSzVyPUCuNFMyOzFizszN	NWHsdFFJW0GQR1XS
K052	NYjiRpJtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF31PYJKSzVyPUCuNFMzPDdizszN	MVrTRW5ITVJ?
KM-H2	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXabodKSzVyPUCuNFM{ODdizszN	M1zzcnNCVkeHUh?=
TE-12	MoPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2jUV2lEPTB;MD6wN\|MxQSEQvF2=	M{Dn[HNCVkeHUh?=
TK10	M1SyNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnXFTWM2OD1yLkCzN\|U3KM7:TR?=	MknFV2FPT0WU
NMC-G1	M3rNU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlnnTWM2OD1yLkCzOFUzKM7:TR?=	NIqwR3hUSU6JRWK=
no-11	MnHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlX6TWM2OD1yLkCzOFc5KM7:TR?=	MmnVV2FPT0WU
NCI-H524	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIrxRmtKSzVyPUCuNFM2OjlizszN	NV71ZnFNW0GQR1XS
MHH-CALL-2	NWfYNYZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnfkTWM2OD1yLkCzOVYzKM7:TR?=	MojrV2FPT0WU
GB-1	NYe0[oFOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{O0NmlEPTB;MD6wN\|Yh\|ryP	NWfBbodJW0GQR1XS
OPM-2	NEj0eG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPxcmJlUUN3ME2wMlA{Pjd\|IN88US=>	MmDyV2FPT0WU
RH-1	NVT4PXNFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHpTWM2OD1yLkCzPFE6KM7:TR?=	MUHTRW5ITVJ?
NCI-H64	MoXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1HETGlEPTB;MD6wN\|g2PyEQvF2=	NYPXc4tkW0GQR1XS
EVSA-T	Mnf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWXmb41jUUN3ME2wMlA{QTJ\|IN88US=>	MV7TRW5ITVJ?
KARPAS-299	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXTTWM2OD1yLkCzPVgh\|ryP	M17ZNXNCVkeHUh?=
MZ7-mel	M1XqZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnnOVJKSzVyPUCuNFQxPCEQvF2=	M{fUU3NCVkeHUh?=
LB373-MEL-D	NXryNmpOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTBwMESxNFUh\|ryP	NELJOXpUSU6JRWK=
HEL	NWfUWWl[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\v[YNXUUN3ME2wMlA1OTRizszN	NXvTXJI3W0GQR1XS
SW872	MkKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnvXTWM2OD1yLkC0NlEh\|ryP	NX;XTocyW0GQR1XS
DU-4475	MkXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIPsd45KSzVyPUCuNFQzPDRizszN	NWXlSnltW0GQR1XS
IST-SL2	NU\xcYZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFnHVnNKSzVyPUCuNFQzPzVizszN	M323XXNCVkeHUh?=
NCI-H82	NEj6WXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3LOSWlEPTB;MD6wOFMxPyEQvF2=	MmC0V2FPT0WU
LC4-1	NFPQOllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{\CU2lEPTB;MD6wOFM2OSEQvF2=	MYDTRW5ITVJ?
HDLM-2	NICxVYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTBwMESzPVIh\|ryP	MWjTRW5ITVJ?
MMAC-SF	NF3XOZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4LEWGlEPTB;MD6wOFU{PCEQvF2=	MXzTRW5ITVJ?
L-540	MmPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPuOolXUUN3ME2wMlA1PjN7IN88US=>	NH;McXJUSU6JRWK=
MZ2-MEL	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPrTWM2OD1yLkC0O\|QzKM7:TR?=	M1LlRnNCVkeHUh?=
LU-134-A	NYrtcIdiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFXnTHdKSzVyPUCuNFQ4PzNizszN	MW\TRW5ITVJ?
UACC-257	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1j2WGlEPTB;MD6wOFg1QSEQvF2=	NU\sUFFGW0GQR1XS
NCI-H1581	MljQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fQXGlEPTB;MD6wOFk2OyEQvF2=	NHjGSZhUSU6JRWK=
NB17	NYj0SGE2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\tZ3RKSzVyPUCuNFQ6PzlizszN	MXLTRW5ITVJ?
SBC-1	M{LpZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH\SfnBKSzVyPUCuNFUxPDJizszN	MkLiV2FPT0WU
TALL-1	NWH0UHhpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUGxPWpWUUN3ME2wMlA2ODR3IN88US=>	MWLTRW5ITVJ?
NCI-H1304	M4HqUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1nJWWlEPTB;MD6wOVIxQCEQvF2=	M2S0VnNCVkeHUh?=
NEC8	MnPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWPQT4JKUUN3ME2wMlA2Ojh4IN88US=>	M1jGZnNCVkeHUh?=
CAL-148	NF;vUllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFmzfVFKSzVyPUCuNFU1OzlizszN	NVfqNo9xW0GQR1XS
CGTH-W-1	NGTQcHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVXJR\|UxRTBwMEW0OFkh\|ryP	MYjTRW5ITVJ?
NCI-H889	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlSyTWM2OD1yLkC1OVkzKM7:TR?=	MYXTRW5ITVJ?
GR-ST	NUnC[FJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3fZbmlEPTB;MD6wOVYzOSEQvF2=	MXvTRW5ITVJ?
KARPAS-422	NXG3SndoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTBwMEW2OUDPxE1?	MYjTRW5ITVJ?
RPMI-8866	NXPwPXB3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2T4WWlEPTB;MD6wOVcyOiEQvF2=	NGSyPJNUSU6JRWK=
SCLC-21H	MnrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmPrTWM2OD1yLkC1PFg1KM7:TR?=	M4OwenNCVkeHUh?=
COR-L88	M{jYcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoOzTWM2OD1yLkC1PVI4KM7:TR?=	M2DqW3NCVkeHUh?=
LU-139	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2D5bWlEPTB;MD6wOVk5PiEQvF2=	Ml\6V2FPT0WU
SF126	Mn7jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGr0dYxKSzVyPUCuNFYyOzNizszN	NGLDPHJUSU6JRWK=
NCI-H1882	MojuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn;MTWM2OD1yLkC2OFI1KM7:TR?=	M{HYVHNCVkeHUh?=
EW-24	NX7xWXFYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3pbVMxUUN3ME2wMlA3PDh\|IN88US=>	MnPMV2FPT0WU
CP67-MEL	M2XmPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkS0TWM2OD1yLkC2PFEh\|ryP	MnPDV2FPT0WU
DG-75	NE\6VJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{D5XGlEPTB;MD6wOlg6QSEQvF2=	NF62dWJUSU6JRWK=
LOXIMVI	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPOTWM2OD1yLkC3NFI5KM7:TR?=	NHvVdoJUSU6JRWK=
HH	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHjWVIRKSzVyPUCuNFcyPTdizszN	MX;TRW5ITVJ?
K5	M{PRemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUDJR\|UxRTBwMEeyNlYh\|ryP	MmDxV2FPT0WU
EC-GI-10	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV\JR\|UxRTBwMEeyOVch\|ryP	MX3TRW5ITVJ?
SK-N-DZ	M1r6ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MljjTWM2OD1yLkC3N\|A4KM7:TR?=	MlL4V2FPT0WU
A3-KAW	MoKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTBwMEezOVEh\|ryP	M3PD[nNCVkeHUh?=
MLMA	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTBwMEe0OlUh\|ryP	NWLqU\|hPW0GQR1XS
LB996-RCC	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWXhRYpiUUN3ME2wMlA4PzB5IN88US=>	NFHqdG9USU6JRWK=
OS-RC-2	NIjnc3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXLb5pKSzVyPUCuNFc4PDhizszN	M1HQfHNCVkeHUh?=
CTB-1	M1[wS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnJdlYyUUN3ME2wMlA4QDFizszN	NGHwZolUSU6JRWK=
IST-MES1	M{\SPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWnM[3JYUUN3ME2wMlA4QTF{IN88US=>	MoHUV2FPT0WU
LS-1034	M1iwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFn0bJNKSzVyPUCuNFgxOzVizszN	NX3HWGUzW0GQR1XS
HT	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHXTWM2OD1yLkC4NFg3KM7:TR?=	MmfRV2FPT0WU
NCI-H2141	MkTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7BSHBpUUN3ME2wMlA5OSEQvF2=	M1P0NHNCVkeHUh?=
LB2518-MEL	M{f3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{C1V2lEPTB;MD6wPFE1OSEQvF2=	NWnnclR1W0GQR1XS
GI-ME-N	M3XMbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnzyTWM2OD1yLkC4OFUzKM7:TR?=	MVvTRW5ITVJ?
TGW	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn[5TWM2OD1yLkC4OlA4KM7:TR?=	NYrNUZU2W0GQR1XS
SK-NEP-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTBwMEi2OFEh\|ryP	M2ThbHNCVkeHUh?=
NOMO-1	MoXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnXb4VKSzVyPUCuNFkzPzVizszN	MVXTRW5ITVJ?
ES6	Moq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{DrUWlEPTB;MD6wPVU5QSEQvF2=	NXPjdGhjW0GQR1XS
NCI-H209	M1v6SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HSZWlEPTB;MD6wPVc5PiEQvF2=	M2naZnNCVkeHUh?=
GAK	MlL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUPQd2h5UUN3ME2wMlExOTZizszN	NVi3Zo5[W0GQR1XS
BC-1	M1Ttc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlT0TWM2OD1yLkGwN\|YyKM7:TR?=	M1\vU3NCVkeHUh?=
KLE	NHnTRVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4j0UGlEPTB;MD6xNFQ1OyEQvF2=	NHPhSnNUSU6JRWK=
EW-3	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHSOIRKSzVyPUCuNVA6QCEQvF2=	MY\TRW5ITVJ?
NKM-1	NGXae2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWW5bHZRUUN3ME2wMlEyOSEQvF2=	NWGwSZl6W0GQR1XS
D-336MG	Mnv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTBwMUGyOFQh\|ryP	MmL1V2FPT0WU
NB69	NYjDWJFrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjRXGRoUUN3ME2wMlEyOzBzIN88US=>	NGG3WHBUSU6JRWK=
D-263MG	NWS3XIhVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXnUOFkyUUN3ME2wMlEyPzF{IN88US=>	NXjFXo5DW0GQR1XS
KP-N-YS	NWPaTmJYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPHb\|BWUUN3ME2wMlEzOjlzIN88US=>	NFnZR\|FUSU6JRWK=
NCI-H1155	NYrUXZM6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;WTWM2OD1yLkGyOVU5KM7:TR?=	MXnTRW5ITVJ?
BOKU	Mmj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUP1eXFxUUN3ME2wMlEzPTd7IN88US=>	M17ubHNCVkeHUh?=
LAMA-84	M3PucWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fsUGlEPTB;MD6xNlk6KM7:TR?=	M2H5fHNCVkeHUh?=
Raji	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTBwMUOxNVch\|ryP	MXXTRW5ITVJ?
LU-65	Mlq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnqxTWM2OD1yLkGzN\|A4KM7:TR?=	NGT4bYVUSU6JRWK=
NCI-H187	M4O4W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;TTWM2OD1yLkGzPVI1KM7:TR?=	Mm\RV2FPT0WU
GCIY	NXH4PXRDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\DRld6UUN3ME2wMlE1QTBzIN88US=>	NV3Hd3J6W0GQR1XS
NCI-H2107	Mn;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\lW3RvUUN3ME2wMlE2ODhizszN	MXjTRW5ITVJ?
NCI-H1522	NYf0UFRsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWfGU457UUN3ME2wMlE2OjZ4IN88US=>	NYfiXFQ6W0GQR1XS
NB6	MmDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\tNJB7UUN3ME2wMlE2PjJ\|IN88US=>	NFi2VWZUSU6JRWK=
EM-2	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFTZflBKSzVyPUCuNVU4ODZizszN	NGnLeHVUSU6JRWK=
HCC2218	MlnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjBcodqUUN3ME2wMlE2QThizszN	M1nEc3NCVkeHUh?=
NCI-H748	NHv3[WNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUXsVFk6UUN3ME2wMlE3Ozd4IN88US=>	MUjTRW5ITVJ?
MS-1	NXiyfHR5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTBwMU[1N\|ch\|ryP	NYDufm01W0GQR1XS
NB5	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\aPGlEPTB;MD6xOlU6PyEQvF2=	MWXTRW5ITVJ?
OMC-1	M3rve2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFn5XHVKSzVyPUCuNVY3QDhizszN	M33UfnNCVkeHUh?=
NCI-H345	M1;EfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\2XlJKSzVyPUCuNVY6OjhizszN	MWPTRW5ITVJ?
L-428	MlzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;6[HNKSzVyPUCuNVY6PDVizszN	MnX3V2FPT0WU
SCH	MkjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGr6VJhKSzVyPUCuNVg3QDVizszN	NWPXVHM6W0GQR1XS
NCI-H1417	NWqwbWV4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LrNWlEPTB;MD6xPVIzPyEQvF2=	M4PSNHNCVkeHUh?=
COLO-320-HSR	MnjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1fsSGlEPTB;MD6xPVU{OiEQvF2=	MkLqV2FPT0WU
BT-474	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTBwMkC4PVIh\|ryP	NWjkWGpSW0GQR1XS
GDM-1	M3Kzc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HyZ2lEPTB;MD6yNVk4OSEQvF2=	NULrWmFkW0GQR1XS
NCI-H2196	NXH5c2pQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHCTWM2OD1yLkKyNlM2KM7:TR?=	MWfTRW5ITVJ?
KP-N-RT-BM-1	MnHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4XZN2lEPTB;MD6yNlM1QSEQvF2=	MoOyV2FPT0WU
KNS-81-FD	Mn:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mon1TWM2OD1yLkKyPVU5KM7:TR?=	M3z0fnNCVkeHUh?=
COLO-668	Mm\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1XJXWlEPTB;MD6yN\|Y4PSEQvF2=	MlXtV2FPT0WU
C2BBe1	Mo\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzUTWM2OD1yLkK2O\|Q4KM7:TR?=	MVLTRW5ITVJ?
Ramos-2G6-4C10	Mof3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnHrTWM2OD1yLkK2PVU1KM7:TR?=	NGHibmJUSU6JRWK=
CAS-1	MlzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkWwTWM2OD1yLkK3NFk3KM7:TR?=	NVzWeYVtW0GQR1XS
GOTO	M3\uSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\3TGlEPTB;MD6yO\|g6PCEQvF2=	MmL6V2FPT0WU
LP-1	NXLIPFFDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkfMTWM2OD1yLkK4NFU4KM7:TR?=	MoftV2FPT0WU
NCI-SNU-1	NFr4fHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEj5XHhKSzVyPUCuNlk1OjJizszN	M{T0OnNCVkeHUh?=
EB-3	Ml\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXvJR\|UxRTBwMkm5O\|kh\|ryP	M{TsRnNCVkeHUh?=
MHH-NB-11	M1\m[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHaU\|JwUUN3ME2wMlMxPDB{IN88US=>	NX[0eXloW0GQR1XS
SK-N-FI	MnG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnm4TWM2OD1yLkOxOlkzKM7:TR?=	NGHzNlFUSU6JRWK=
HCC2157	M{Pnfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTBwM{O5NVMh\|ryP	MoHzV2FPT0WU
SIMA	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfuRZBtUUN3ME2wMlM1PThzIN88US=>	M1\FO3NCVkeHUh?=
MDA-MB-134-VI	Mon6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWT4ZZkyUUN3ME2wMlM3QTJ6IN88US=>	M3;ib3NCVkeHUh?=
NCI-H1694	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVjOZphGUUN3ME2wMlM4KM7:TR?=	Mn\MV2FPT0WU
EHEB	NUjwcFRST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVq3dpRoUUN3ME2wMlM6ODh3IN88US=>	M17lUHNCVkeHUh?=
U-266	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7lVXNkUUN3ME2wMlM6QDR4IN88US=>	NGLHNGVUSU6JRWK=
LC-1F	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGD0W2FKSzVyPUCuOFM4PjVizszN	NX7We3ZwW0GQR1XS
SHP-77	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWCwRllrUUN3ME2wMlQ4QDV3IN88US=>	NX7FOZJZW0GQR1XS
LS-513	MnO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{jBVGlEPTB;MD60PVMxPyEQvF2=	NVjEVZlnW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-ERK / ERK; PubMed: 20068074 Clin Cancer Res Paclitaxel pulse induces phospho-ERK. Paclitaxel (6ug/mL) was pulsed over 10min to 4hr prior to cell harvesting. A biphasic activation is observed in the resistant cells. MARCKS (pSer159/163); PubMed: 26015406 Oncotarget Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis. Src (pTyr416); PubMed: 26015406 Oncotarget Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis. p-JAK2 / p-STAT3 / p-AKT / p-MAPK / Bcl-xl / MCL-1; PubMed: 29849942 Oncotarget OVCAR-8 and MDAH2774 cells were treated with ruxolitinib (20 μM), paclitaxel (10 nM) or the combination for 24 h. Whole cells were collected and determined for the change of STAT3, AKT and ERK pathways and expression of BCL-XL and MCL-1 by Western blot. Id1; PubMed: 25344919 Oncotarget (A) Paclitaxel suppressed Id1 expression in H520 cells in a time-dependent manner. MARCKS; PubMed: 26015406 Oncotarget Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.	20068074 26015406 29849942 25344919
Growth inhibition assay	Cell viability; PubMed: 28823711 Biol Psychiatry Paclitaxel reduces HeyA8 tumor cell viability in MTT assay.	28823711
Immunofluorescence	α-tubulin; PubMed: 22904633 Int J Nanomedicine Cellular α-tubulin (red) was blotted by immunostaining and subsequent confocal microscopy 3 hours after A549 cells were treated with 12.5 nM of paclitaxel and 12.5 nM of PLGA-PEI-TAX, respectively. The same experiment was performed with 62.5 nM of paclitaxel and 62.5 nM of PLGA-PEI-TAX in A549/T12 cells. PLGA-PEI-TAX, poly(lactic-co-glycolic acid)-polyethylenimine nanoparticles loaded with paclitaxel. Rab11a/BV9; PubMed: 29290815 Theranostics Paclitaxel reversed the DAVLBH-mediated inhibition of internalized VE-cadherin recycling back to the cell membrane. HUVECs pretreated with or without paclitaxel were treated with or without DAVLBH for 4 h. Quantification of BV9/Rab11a colocalization is shown (n = 3).	22904633 29290815

In vivo

The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. ^[4]

Protocol

Cell Research: ^[1]	+ Expand Cell lines: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs Concentrations: 0.1-100 pM Incubation Time: 72 hours Method: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well. (Only for Reference)
Animal Research: ^[4]	+ Expand Animal Models: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors Formulation: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use. Dosages: 20 mg/kg Administration: Administered via i.v. (Only for Reference)

Cell Research:

^[1]

+ Expand

Cell lines: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
Concentrations: 0.1-100 pM
Incubation Time: 72 hours
Method:
Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.

(Only for Reference)

Animal Research:

^[4]

+ Expand

Animal Models: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
Formulation: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
Dosages: 20 mg/kg
Administration: Administered via i.v.
(Only for Reference)

References

[4] Chang J, et al. Breast Cancer Res Treat. 2012.

+ Expand

Solubility (25°C)

In vitro	DMSO	171 mg/mL (200.25 mM)
	Ethanol	18 mg/mL (21.07 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+5% Tween 80+ddH2O For best results, use promptly after mixing.	2.5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Paclitaxel SDF

Molecular Weight	853.91
Formula	C₄₇H₅₁NO₁₄
CAS No.	33069-62-4
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	NSC 125973

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03400306	Not yet recruiting	Cancer - Ovarian	AbbVie	May 10 2020	Phase 1
NCT03400306	Not yet recruiting	Cancer - Ovarian	AbbVie	May 10 2020	Phase 1
NCT03417921	Not yet recruiting	Pancreatic Cancer	Ability Pharmaceuticals SL\|The Cleveland Clinic	December 1 2019	Phase 1\|Phase 2
NCT03417921	Not yet recruiting	Pancreatic Cancer	Ability Pharmaceuticals SL\|The Cleveland Clinic	December 1 2019	Phase 1\|Phase 2
NCT03818997	Not yet recruiting	Esophageal Cancer\|Biliary Tract Cancer\|GastroEsophageal Cancer\|Hepatobiliary Neoplasm	European Organisation for Research and Treatment of Cancer - EORTC\|Hoffmann-La Roche\|Leap Therapeutics Inc.	August 2019	Phase 2
NCT03818997	Not yet recruiting	Esophageal Cancer\|Biliary Tract Cancer\|GastroEsophageal Cancer\|Hepatobiliary Neoplasm	European Organisation for Research and Treatment of Cancer - EORTC\|Hoffmann-La Roche\|Leap Therapeutics Inc.	August 2019	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?
Answer:
S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.
Question 2:
the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?
Answer:
Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products0

TAI-1 ^New

TAI-1 is a potent and specific Hec1 inhibitor, which disrupts Hec1-Nek2 protein interaction.
Docetaxel Trihydrate ^New

Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.
Combretastatin A4 ^New

Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with K_d of 0.4 μM.Phase 3.
Docetaxel

Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.
Vincristine sulfate

Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.
Nocodazole

Nocodazole is a rapidly-reversible inhibitor of microtubule polymerization, also inhibits Abl, Abl(E255K) and Abl(T315I) with IC50 of 0.21 μM, 0.53 μM and 0.64 μM in cell-free assays, respectively. Nocodazole improves the CRISPR-mediated HDR efficiency and has an additive effect on enhancing precise genome editing.
Vinorelbine Tartrate

Vinorelbine Tartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin.
Cabazitaxel

Cabazitaxel is a semi-synthetic derivative of a natural taxoid that kills cancer cells by inhibiting cell division and growth. Cabazitaxel exerts its effects by inhibiting microtubule growth and assembly, processes that are essential for cells to divide.

Features:A semi-synthetic derivative of a natural taxoid.
Patupilone (EPO906, Epothilone B)

Patupilone (EPO906, Epothilone B) is a paclitaxel-like microtubule-stabilizing agent with EC_0.01 of 1.8 μM. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Paclitaxel

Cited by 25 Publications

6 Customer Reviews

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Paclitaxel SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products0

Choose Your Country or Region

By Signaling Pathways

By product type

Paclitaxel

Cited by 25 Publications

6 Customer Reviews

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Paclitaxel SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products0

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)